APC has submitted responses to an environmental scan request from FDA’s Center for Veterinary Medicine (CVM). This feedback is intended to provide perspective and allow the agency to address weaknesses.
If you haven’t joined APC’s group purchasing deal with Worldpay, you might be throwing away money.
In a significant ruling this week, a U.S. district judge granted SCA's request and issued a sealed temporary restraining order to block FDA from publishing unsupported concerns about the sterility of the 503B facility.
This year, we have 36 Corporate Patrons signed on in support of APC, including 22 Tier Corporate Patrons.
The professional development event of the year for compounding pharmacy and facility owners and managers is back, and it’s better than ever.
It was another week of interesting reporting on GLP-1s—compounded, counterfeit, and commercially available. APC continues to field multiple media inquiries each week about the GLP-1 craze and compounding’s role in shortages.
We’ve got some new tools to help you educate and inform prescribers about the threat to compounded hormone therapy.
APC submitted comments this week on FDA’s Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act.
In a listening session with representatives from FDA’s Center for Drug Evaluation & Research this week, APC leaders again pressed FDA to support a proposal to eliminate the MOU on interstate shipments of compounded medications.
This week, just two weeks into the new year, in a special-called APC Board of Directors meeting, I resigned as your 2024 APC Board Chair effective January 31. On February 1, I will join the APC staff as Chief Advocacy Officer.
FOLLOW US
